The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved Wainzua (eplontersen) to treat adults with ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved trofolastat (RoTecPSMA), the first prostate-specific membrane antigen (PSMA)-targeting product authorised for use with ...

Panellists at the OBN BioTrinity 2025 conference in London discussed how US uncertainty is impacting the biopharma ...

On March 17, 2025, the government published a policy paper with an Action Plan for regulation and regulators, outlining how it intends to reform ...

PLC (AIM: 4BB) (“4basebio”), a company which develops and commercializes the large-scale manufacture of synthetic DNA as well as nanoparticle delivery solutions, today announced that it has received ...

The MHRA has introduced seven new CERSIs to modernise healthcare regulation and accelerate patient access to innovative ...

A new study from Queen Mary University of London found that 9% of all reported adverse drug reactions (ADRs) reported to the ...

CHMP recommends approval for XOANACYL, an oral therapy for use in the following therapeutic areas: Iron deficiency, chronic renal failure and ...

Entrada Therapeutics has secured authorisation from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) and ...

4basebio PLC has been granted Good Manufacturing Practice (GMP) certification by the UK’s Medicines and Healthcare products ...

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted approval for trofolastat (RoTecPSMA), a prostate-specific membrane antigen (PSMA)-targeting agent for detecting ...